Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    Welcome !
    My account
    Logout

Aerie Pharmaceuticals Inc (AERI) Stock Forecast 2025 - AI Price Prediction & Analysis

Aerie Pharmaceuticals Inc (AERI) AI Stock Price Forecast & Investment Analysis

Aerie Pharmaceuticals Inc Stock Price Chart and Technical Analysis

Loading Aerie Pharmaceuticals Inc interactive price chart and technical analysis...

Aerie Pharmaceuticals Inc (AERI) - Comprehensive Stock Analysis & Investment Research

Deep dive into Aerie Pharmaceuticals Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Aerie Pharmaceuticals Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Aerie Pharmaceuticals Inc: Aerie Pharmaceuticals Inc operates in the Manufacturing sector, making it an emerging small-cap investment.

Aerie Pharmaceuticals Inc (Stock Symbol: AERI) is a leading company in the Manufacturing sector , specifically operating within the Biological Product (except Diagnostic) Manufacturing industry.

The organization employs approximately 365 professionals worldwide and operates under the strategic leadership of CEO Vicente Anido.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Aerie Pharmaceuticals Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aerie Pharmaceuticals Inc: With $201M in annual revenue and -34.2% net margin, the company demonstrates developing profitability.

Annual Revenue: $201 million generating a -34.2% net profit margin .

Market Capitalization: $753 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -663.1% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Aerie Pharmaceuticals Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Aerie Pharmaceuticals Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Aerie Pharmaceuticals Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Aerie Pharmaceuticals Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Aerie Pharmaceuticals Inc: Market positioning analysis based on available financial and operational metrics.

Aerie Pharmaceuticals Inc strategically competes in the highly dynamic Biological Product (except Diagnostic) Manufacturing marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 86.6% gross margin, indicating strong pricing power and operational efficiency.

Aerie Pharmaceuticals Inc (AERI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Aerie Pharmaceuticals Inc stock analysis.

Loading Aerie Pharmaceuticals Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Aerie Pharmaceuticals Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Aerie Pharmaceuticals Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Aerie Pharmaceuticals Inc: With a P/E ratio of -5.39, the market sees the stock as potentially undervalued.

P/E Ratio -5.39x
P/B Ratio -4.59x
Market Cap $753M
EPS $-2.59
Book Value/Share $-3.32
Revenue/Share $4.33
FCF/Share $-2.59
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Aerie Pharmaceuticals Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Aerie Pharmaceuticals Inc: An ROE of -663.1% indicates room for improvement in shareholder value creation.

ROE -663.1%
ROA -18.1%
ROIC -21.8%
Gross Margin 86.6%
Operating Margin -22.8%
Net Margin -34.2%
EBT Margin -33.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Aerie Pharmaceuticals Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Aerie Pharmaceuticals Inc: A current ratio of 2.75 indicates strong liquidity.

Current Ratio 2.75x
Quick Ratio 2.25x
D/E Ratio 9.20x
Financial Leverage 16.77x
Interest Coverage -1.9x
Working Capital $227M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Aerie Pharmaceuticals Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Aerie Pharmaceuticals Inc: Free cash flow of $-11M indicates cash challenges that need attention.

Operating Cash Flow $-7M
Free Cash Flow $-11M
Capital Spending $-4M
FCF/Sales -5.6%
CapEx/Sales 2.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Aerie Pharmaceuticals Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Aerie Pharmaceuticals Inc: An asset turnover of 0.53x suggests room for improvement in asset utilization.

Asset Turnover 0.53x
Receivables Turnover 3.7x
Inventory Turnover 0.8x
Fixed Assets Turnover 2.9x
Days Sales Outstanding 100 days
Days Inventory 464 days
Payables Period 98 days
Cash Conversion Cycle 466 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Aerie Pharmaceuticals Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Aerie Pharmaceuticals Inc: With annual revenue of $201M, Aerie Pharmaceuticals Inc demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $201M
Operating Income $-26M
Net Income $-20M
R&D Expense $88M
SG&A Expense $68M
Cost of Goods Sold $24M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 80%
Cash & Short-term Investments 49%
Total Liabilities 132%
Short-term Debt 72%
Accounts Receivable 16%
Inventory 10%
Dividend & Shareholder Information
Shares Outstanding 49M
Growth Metrics (YoY)
EPS Growth -17.0%

Latest Aerie Pharmaceuticals Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Aerie Pharmaceuticals Inc (AERI) stock price and investment outlook.

Aerie Pharmaceuticals Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Aerie Pharmaceuticals Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Aerie Pharmaceuticals Inc Stock Forecast

How accurate are Aerie Pharmaceuticals Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for AERI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Aerie Pharmaceuticals Inc stock price forecasts?

Our analysis considers Aerie Pharmaceuticals Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Aerie Pharmaceuticals Inc a good investment in 2025?

Based on our AI analysis, Aerie Pharmaceuticals Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Aerie Pharmaceuticals Inc forecasts updated?

Aerie Pharmaceuticals Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Aerie Pharmaceuticals Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Aerie Pharmaceuticals Inc stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...